

Regioselective Galactofuranosylation for the Synthesis of Disaccharide Patterns Found in Pathogenic Microorganisms

Laurent Legentil, Yari Cabezas, Olivier Tasseau, Charles Tellier, Franck Daligault, Vincent Ferrières

► To cite this version:

Laurent Legentil, Yari Cabezas, Olivier Tasseau, Charles Tellier, Franck Daligault, et al.. Regioselective Galactofuranosylation for the Synthesis of Disaccharide Patterns Found in Pathogenic Microorganisms. *Journal of Organic Chemistry*, American Chemical Society, 2017, 82 (14), pp.7114-7122. 10.1021/acs.joc.7b00565 . hal-01578548

HAL Id: hal-01578548

<https://hal-univ-rennes1.archives-ouvertes.fr/hal-01578548>

Submitted on 13 Sep 2017

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Regioselective galactofuranosylation for the synthesis of disaccharide patterns found in pathogenic microorganisms

Laurent Legentil,^{* a} Yari Cabezas,^a Olivier Tasseau,^a Charles Tellier,^b Franck Daligault^b and

Vincent Ferrières^{* a}


(a) *Ecole Nationale Supérieure de Chimie de Rennes, CNRS, UMR 6226, 11 Allée de*

Beaulieu, CS 50837, 35708 Rennes Cedex 7, France

(b) *Université de Nantes, UMR CNRS 6286, 2 Rue de la Houssinière, 44322 Nantes Cedex 3,*

France

laurent.legentil@ensc-rennes.fr or vincent.ferrieres@ensc-rennes.fr



Abstract: Koenigs-Knorr glycosylation of acceptors with more than one free hydroxyl group by 2,3,5,6-tetrabenzoyl galactofuranosyl bromide was performed using diphenylborinic acid 2-aminoethyl ester (DPBA) as inducer of regioselectivity. High regioselectivity for the glycosylation on the equatorial hydroxyl group of the acceptor was obtained thanks to the transient formation of a borinate adduct of the corresponding 1,2-*cis* diol. Nevertheless formation of orthoester by-products hampered the efficiency of the method. Interestingly electron-withdrawing groups on *O*-6 or on *C*-1 of the acceptor displaced the reaction in favour of the desired galactofuranosyl containing disaccharide. The best yield was obtained for the furanosylation of *p*-nitrophenyl 6-*O*-acetyl mannopyranoside. Precursors of other disaccharides, found in the glycocalix of some pathogens, were synthesized according to the same protocol with yields ranging from 45 to 86%. This is a good alternative for the synthesis of biologically relevant glycoconjugates.

Introduction

The significant discoveries on the organization of the cell, either from prokaryote or eukaryote origin, have pointed out the key role of the glycocalix, the complex layer of hetero- and oligosaccharides that surrounds the cell wall.¹⁻⁴ Even if most cells use common sugars to build this glycocalix, they manage to differentiate from each other thanks to the infinite possibilities of sequence and the nature of the linkages involved. Intriguingly some microorganisms incorporate carbohydrates in their furanose form rather than in their pyranose one in order to further differentiate themselves from other organisms.^{5,6} In particular D-galactofuranose (D-Galf) containing glycoconjugates are found in large amount in pathogenic microorganisms like *Mycobacteria* or *Leishmania* but are absent in the mammalian kingdom.⁷ Owing to the key role played by such motifs in the virulence or survival of the parasite or bacteria, numerous groups have developed evolved synthetic pathways to access to such Galf-containing oligosaccharides.⁸⁻¹³ Alternatively galactofuranosyl-transferases isolated from mycobacteria or furanosylhydrolases involved in the degradation of biomass have been used to obtain either oligomers of Galf^{14,15} or heterodisaccharides.^{16,17} These last strategies involve a minimum of protecting group manipulation as biocatalysts are able to selectively transfer a furanosyl entity on a specific position of an acceptor.

Attempt to mimic such selectivity remains the grail for glycochemists. Already, regioselective glycosylation of naked acceptors could be performed thanks to transient selective activation of one hydroxyl group against the others using for example dibutyltin(IV) oxide^{18,19} or aryl borinic acid^{20,21} as inducers of regioselectivity. More recently, Taylor and coworkers developed new diarylborinic acid derivatives for the regioselective acylation,²² alkylation²³ or tosylation²⁴ of the secondary alcohol of various alkyl glycosides. They postulated that diarylborinic acid could form tetracoordinate adducts with 1,3-diols and 1,2-*cis* diols thus increasing the nucleophilicity of either the primary hydroxyl group or the least hindered

1
2
3 equatorial one. The methodology was recently extended to the glycosylation of thiophenyl
4
5 mannopyranoside using D-arabinofuranosyl methanesulfonate as a donor.²⁵ It is the first
6
7 example of the synthesis of furanosyl containing disaccharides obtained by this methodology
8
9 and works remain to be done to apply such process to the synthesis of hexofuranosyl-
10
11 containing conjugates.
12

13
14 After having proposed to work with unprotected thioimidates as donors,²⁶ we now report on
15
16 the use of diphenylborinic acid 2-aminoethyl ester (DPBA) to induce regioselectivity for
17
18 galactofuranosylation of various glycosidic acceptors: D-mannopyranosides (D-Man_p), D-
19
20 galactopyranoside (D-Galp), N-acetyl-D-galactopyranoside (D-GalpNAc), L-
21
22 rhamnopyranoside (L-Rhap) and D-Galf. The target compounds are disaccharidic parts of
23
24 biomolecules anchored to the cell wall of pathogenic microorganisms (Figure 1).^{5,6}
25
26 Representative examples include β-(1→3) and (1→6)-D-Man_p linkage found in *Aspergillus*,
27
28 *Trypanosoma* or *Leishmania* sp.; β-(1→3)-D-Galp or β-(1→3)-D-GalpNAc linkage identified
29
30 in *Bacteroides*, *Fibrobacter* or *Agelas* sp. for the first one or *Bacteroides* and *Shigella* for the
31
32 second one; β-(1→4)-L-Rhap bond presented by *Mycobacterium*.^{6,27} Wide ligation diversity
33
34 was also established between two D-Galf entities: β-(1→5) and β-(1→6) found in particular in
35
36 *Mycobacterium tuberculosis*, *Cryphonectria parasitica* and *Aspergillus*.²⁸
37
38

39
40 Some of these disaccharides linked the Galf non-reducing end to the most nucleophilic
41
42 equatorial oxygen of the sugar at the reducing end. This oxygen is in addition in a 1,2-*cis*
43
44 configuration with one of the proximal hydroxyl group. Such glycosidic bonds could therefore
45
46 be selectively obtained thanks to glycosylation in presence of diarylborinic inducer. First the
47
48 conditions of glycosylation were optimized with mannopyranosidic acceptor using
49
50 peracylated galactofuranosyl bromide as donor. Different groups were introduced on the
51
52 acceptor either on the primary hydroxyl group or at the anomeric position in order to
53
54 investigate the influence of the inductive effect on the glycosylation. An attempt of
55
56
57
58
59
60

rationalization of the results was performed thanks to *ab initio* calculation. Finally the methodology was extended to the other relevant acceptors.




FIGURE 1. Natural occurrence of galactofuranose in some glyocalix of selected organisms.

Results and discussion

Our aim is to develop a regio- and stereoselective glycosylation to obtain Galf-containing disaccharides. The conditions developed by Taylor²⁹ were first applied on a model reaction between various Galf donors and Manp acceptors (Figure 2). Different activating groups were introduced from peracylated derivatives of galactofuranose, namely the bromide,³⁰ the thiophenyl³¹ or the trichloroacetimidate³² according to available protocols to give **1a**, **1b** and **1c** respectively. As for the acceptors, we decided to evaluate the influence of the protecting group on both positions C-1 and O-6. The primary position has to be masked anyway in order to avoid glycosylation at this position. Starting from commercially available *p*-nitrophenyl mannopyranoside (*p*NP Manp) **2a**, the electron-donating group *tert*-butyldimethylsilyl was first introduced on position O-6 by action of the corresponding silylating agent TBSCl in presence of imidazole and DMAP with a moderate 40% yield. The electron-withdrawing group acetyl on the other hand was added using vinyl acetate in THF in presence of the supported lipase from *Candida antartica* (CAL-B). This last strategy was also applied to the

octyl and thiotolyl α -Manp **3a** and **3b** to obtain the corresponding 6-*O*Ac mannoside **4a** and **4b** with 89% and 69% yields respectively.





FIGURE 2. Building blocks used in the regioselective glycosylation.

With the donors **1** and acceptors **2** in hand, different attempts of glycosylation were implemented (Table 1). Following the findings of Taylor and coworkers, a catalytic amount of diphenylborinic acid 2-aminoethyl ester (DPBA) was used first (Entries 1, 3 to 7). The reactions proceeded in acetonitrile in presence of molecular sieves 4Å in order to limit the hydrolysis of the donors **1**. These donors were used also in excess in the case where the hydrolysis is too high. With TBS Manp **2b** as acceptor and bromide **1a** as donor, the reaction proceeded quickly in presence of both silver oxide and the borinic acid to give the target disaccharide **5b** in 36% yield (Entry 1). It was unambiguously characterized thanks to ¹H and ¹³C NMR spectroscopy. The isolated disaccharide presented an anomeric proton at 5.55 ppm associated with a carbon at 103.8 ppm. Coupling constant $J_{H1,H2}$ was almost zero, a typical value for an anomeric proton of a furanoside in 1,2-*trans* configuration. The regioisomery of the disaccharide was further confirmed by 2D-NMR HMBC experiments. A long range correlation between C_{Gal}-1 and H_{Man}-3 indicated a (1→3)-glycosidic bond. The other product

1
2
3 of the reaction, and the major one, was identified as the orthoester **6b**. It showed a
4
5 characteristic signal in ^1H NMR at 6.47 ppm associated with a carbon at 105.3 ppm. The
6
7 related coupling constant $J_{\text{H}_1,\text{H}_2}$ reached 4.4 Hz thus indicating a 1,2-*cis* configuration. In
8
9 addition ^{13}C NMR showed a carbon at 123.3 ppm assigned to the quaternary carbon of the
10
11 orthoester function.
12

13
14 For comparative purpose, we tested the absence of DPBA (Entry 2) or of TBS on the primary
15
16 hydroxyl group of the acceptor (Entry 3). Both conditions led to a complex mixture of
17
18 products. As expected when no borinic acid was added the glycosylation occurred on different
19
20 positions of the acceptor and the disaccharide **5b** was isolated in only 10% yield. Also no
21
22 protecting group on *O*-6 resulted in the concomitant glycosylation of both positions 3 and 6,
23
24 the two positions that were activated by the inducers of regioselectivity.²⁹ In these conditions
25
26 only trisaccharide 3,6-di-*O*-(β -D-Galf)-D-Manp could be isolated.
27
28

29
30 Then we tried to isomerize the orthoester **6b** into **5a** by heating the reaction media or by the
31
32 addition of a Lewis acid but only the degradation of the orthoester occurred. Alternatively
33
34 another halogenophile, the silver triflate was used as promoter as it is known to avoid
35
36 orthoester formation. However in these acidic conditions, the TBS group has been cleaved
37
38 and again the trisaccharide 3,6-di-*O*-(β -D-Galf)-D-Manp was obtained. Therefore the silyl
39
40 group was swapped by an acetyl one. After reaction between **1a** and **2c** (Entry 4), the major
41
42 product remained the orthoester **6c** and **5c** was obtained only in 19% yield. As the acetyl
43
44 group is tolerant to acidic condition, silver triflate was this time used successfully as promoter
45
46 (Entry 5). It allowed to access to **5c** with a better yield and no orthoester was isolated.
47
48 However other regioisomers, the *p*NP β -D-Galf-(1 \rightarrow 2)-D-Manp and *p*NP β -D-Galf-(1 \rightarrow 4)-D-
49
50 Manp were formed as well. It confirms that acidic conditions are detrimental to the formation
51
52 of the borinate complex.²⁴ Finally, when other Galf donors **1b** and **1c** were used (Entries 6 and
53
54
55
56
57
58
59
60 7), the yield did not improve and the regioselectivity was poorer as previously reported.²⁹

TABLE 1. Optimization of the conditions for the regioselective galactofuranosylation of *p*NP Manp derivatives.

Entry	Donor (2 eq.)	Acceptor (1 eq.)	Promoter (1 eq.)	DPBA (eq.)	Solvent	Time (h)	5 (Yield %)	Ratio 5:6:7
1	1a	2b	Ag ₂ O	0.1	CH ₃ CN	2	5b (36)	5:6:0
2	1a	2b	Ag ₂ O	-	CH ₃ CN	28	5b (10)	Mixture
3	1a	2a	Ag ₂ O	0.1	CH ₃ CN	2	-	Trisaccharide ^a
4	1a	2c	Ag ₂ O	0.1	CH ₃ CN	19	5c (19)	1:2.4:0
5	1a	2c	AgOTf	0.1	CH ₃ CN	19	5c (33)	13:0:2 ^b
6	1b	2c	NIS, AgOTf	0.1	CH ₃ CN	19	-	-
7	1c	2c	TMSOTf	0.1	CH ₃ CN	19	5c (25)	8:0:2 ^c
8	1a	2b	Ag ₂ O	1	CH ₃ CN	6	5b (46)	7:3:0
9	1a	2b	Ag ₂ O	1	CH ₂ Cl ₂	8	5b (40)	1:0:0
10	1a	2b	Ag ₂ O	1	THF	8	5b (25)	1:1:0
11	1a	2c	Ag ₂ O	1	CH ₃ CN	2	5c (85)	1:0:0
12	1a	2c	AgOTf	1	CH ₃ CN	19	5c (80)	1:0:tr ^c


^a Mainly *p*NP 3,6-di-O-(β-D-Galf)-D-Manp. ^b Mainly *p*NP β-D-Galf-(1→2)-D-Manp and *p*NP β-D-Galf-(1→4)-D-Manp. ^c Mainly *p*NP β-D-Galf-(1→4)-D-Manp

Interestingly, when a stoichiometric amount of DPBA was used, the yield greatly improved and no or trace amount of orthoester was formed (Entries 8 to 12). In addition the use of alternative solvents like THF or dichloromethane decreased either the yields or the selectivity (Entries 9 and 10). Also, the glycosylation of 6-*O*-TBS Manp **2b** proceeded with lower yields than with 6-*O*-Ac Manp **2c**, and a higher amount of orthoester **6b** was isolated (Entries 8 vs. 11). As for the promoter, the acidic AgOTf can be used but trace amount of regioisomers (mainly β-(1→4)-) contaminated again the disaccharide **5c** (Entry 12). The best result was

obtained using the bromide **1a** as donor, activated by one molar ratio of silver oxide, the 6-*O*-acetyl acceptor **2c**, DPBA (one equivalent), in acetonitrile. Under these conditions, the *p*NP β-D-Galp-(1→3)-α-D-Man_p compound **5c** was obtained in a quite worthy yield of 85% with no contamination by the orthoester (Entry 11).

Following this optimization, the methodology was then applied to 6-*O*-acetylated mannosidic acceptors **4a** and **4b** (Table 2) that differ on the nature of the substituent attached to the anomeric position. On one hand, the presence of the electron-donating group octyl at the anomeric position seemed to favour greatly the formation of the orthoester **9a** (Entry 1). Solely the use of silver trifluoromethanesulfonate instead of silver oxide allowed isolating the target compound **8a** with 57% yield (Entry 2). Once again, contamination by other regioisomers hampered the use of such acidic promoter. On the other hand, a completely different outcome arose with a thiotolyl group on C-1 of the mannose as the donor **1a** easily glycosylated the position 3 of the mannoside **4b**. Formation of the orthoester **9b** was low and no other regioisomers were isolated (Entry 3 and 4). It confirms the great influence of the electron-density of the substituent on both position *O*-6 and *C*-1.

TABLE 2. Extension to octyl and thiotolyl mannoside.



Entry	Acceptor	Promoter	Time (h)	Disaccharide (Yield %)	Ratio 8:9:10
1	4a	Ag ₂ O	2	8a (40)	45:55:0
2	4a	AgOTf	5	8a (57)	4:0:1 ^a
3	4b	Ag ₂ O	2	8b (96)	95:5:0
4	4b	AgOTf	6	8b (69)	1:0:0

^a Mainly octyl β-D-Galp-(1→4)-D-Man_p.

To explain these results, we decided to compare the difference of reactivity of the tested acceptors **2b**, **2c**, **4a** and **4b** in complex with diphenylborinic acid using DFT calculation in the gas-phase (B3LYP/6-31+G*) (Table 3 and Supporting Information).

TABLE 3. Calculated Mulliken charges and Fukui indexes of diphenylborinate adduct of **2b, **2c**, **4a** and **4b** (B3LYP/6-31+G*).**

Entry	Mannoside acceptor	Mulliken charge at <i>O</i> -3	f_k at <i>O</i> -3
1	2b	-0.35	0.180
2	2c	-0.31	0.115
3	4a	-0.32	0.135
4	4b	-0.33	0.115

Surprisingly, the estimation of the Mulliken charges on the most reactive equatorial oxygen *O*-3 did not vary much between the different mannosides. Only the Fukui index f_k , a measure of the strength of the nucleophile,³³ decreased significantly with the presence of electron-withdrawing groups either on *O*-6 or on *C*-1. Interestingly, those molecules **2c** and **4b** also formed no or trace amount of orthoesters. On the contrary, electron-donating groups like the TBS (**2b**) or the alkyl (**4a**) one reinforced the nucleophilicity on *O*-3. Those acceptors generated after glycosylation the largest amount of orthoester. Orthoesters are known to form in various amounts during Koenigs-Knorr glycosylation.³⁴ According to Taylor *et al*'s work on pyranosyl bromide,²⁹ the formation of such orthoester is not favoured because the reaction pathway follows a pure S_N2 mechanism. Here, the presence of the bromide in a 1,2-*trans* configuration and the assistance of the benzoyl group on *O*-2 favour the transient acyloxonium specie and not the oxonium intermediate (Figure 3). The formation of such intermediate is in addition predominant in the furanose series.³⁵ The attack of the nucleophile could then occur either at the quaternary carbon or at the anomeric one *via* an S_N2

mechanism. Strong nucleophiles like **4a** or **2b** reacted first at the quaternary carbon and then at the anomeric position leading to a mixture of orthoester and disaccharide. The resulting orthoesters were stable enough to be isolated by silica gel chromatography.³⁶ On the contrary, if less nucleophilic acceptors **2c** and **4b** were used, the attack occurred only at the anomeric center to give the corresponding disaccharides **5c** and **8b**. For the moment we are not able to decide if such selectivity is under kinetic or thermodynamic control. Nevertheless these results could be compared with the armed/disarmed effect linked with the nature of the substituent on the donor. Such activating/deactivating effects are however rarely reported when dealing with the acceptor and thus pave the way to a new understanding of the acceptor reactivity.




FIGURE 3. Mechanism of the formation of the orthoester and the disaccharide according to the nucleophilicity of the acceptor.

The same trend of reactivity was observed when the furanosylation assisted by DPBA was extended to the acceptors *p*NP galactopyranoside **12**, *N*-acetyl-galactosamine **14**, L-rhamnoside **15** and galactofuranoside **16** (Table 4). The building blocks **12** and **14** were obtained through biocatalysed acetylation as before (Figure 4)^{21,37,38} while **15** and **16** came from commercial sources.





FIGURE 4. Acceptors used to obtain Galf-containing disaccharides found in various microorganisms.

On one hand **12** that bears electron-withdrawing groups on *O*-6 and *C*-1 and shows a low Fukui index at *O*-3, gave the corresponding disaccharide **17** with excellent yield and without formation of the orthoester (Entry 1). On the other hand the 6-deoxy-hexose **15** is rather nucleophilic and during the regioselective furanosylation catalysed by silver oxide, more than 30% of orthoester was formed (Entry 4). Alternative silver triflate protocol allowed to increase the yield for disaccharide **19** to 59% but the regioselectivity was decreased and 20% of the regioisomer *p*NP β -Galf-(1 \rightarrow 4)-L-Rhap was obtained as well (Entry 5). Surprisingly, *p*NP *N*-acetyl-galactosamine **14** whose calculated Fukui index was very low, gave the corresponding disaccharide **18** with poor yield (Entry 2). The amount of the corresponding orthoester was also low. The low nucleophilicity of *O*-3, due to the presence of the acetamide group on *C*-2 could explain the poor yield for the glycosylation.³⁹ However 55% yield could be reached with silver triflate as promoter with the downside formation of regioisomers (Entry 3).

The last acceptor tested in the regioselective glycosylation was the *p*NP Galf **16**. In presence of the DPBA, we were expecting to form the diphenylborinate adduct between the *O*-6 and the *O*-5 and thus exacerbating the nucleophilicity of the primary hydroxyl group. Indeed the reaction between the bromide furanosyl **1a** and *p*NP Galf **16** in presence of the borinic acid

and silver oxide led quickly to the total conversion of the acceptor (Entry 6). The minor product of the reaction was then identified as the targeted *p*NP β -Gal f -(1 \rightarrow 6)-Gal f **20** thanks to 2D-NMR experiments. The major one was the orthoester derivative isolated in 56% yield. This was expected as primary hydroxyl groups are much more reactive than secondary hydroxyl groups thus leading to high Fukui index and therefore to a high ratio of orthoester. It is worth to mention nevertheless that no other regioisomer was isolated which means that DPBA indeed formed a complex with *O*-6 and *O*-5 of the Gal f moiety. Finally to prevent from the formation of the orthoester, silver triflate was used and allowed to obtain **20** with 45% yield in mixture with the regioisomer *p*NP β -Gal f -(1 \rightarrow 5)-Gal f (Entry 7).

TABLE 4. Extension to relevant acceptors to obtain Gal f -containing disaccharides.



Entry	Acceptor	f_k	Promoter	Product (Yield %)	By-product (%)
1	12	0.121 ^a	Ag ₂ O	17 (86)	None
2	14	0.101 ^a	Ag ₂ O	18 (10)	Orthoester (37)
3			AgOTf	18 (55 ^c)	β -Gal f -(1 \rightarrow 4)-Gal p NHAc (20)
4	15	0.134 ^a	Ag ₂ O	19 (45)	Orthoester (33)
5			AgOTf	19 (59 ^c)	β -Gal f -(1 \rightarrow 4)-L-Rhap (20)
6	16	0.157 ^b	Ag ₂ O	20 (12)	Orthoester (56)
7			AgOTf	20 (45 ^c)	β -Gal f -(1 \rightarrow 5)-Gal f (10)

^a Fukui index at *O*-3. ^b Fukui index at *O*-6. ^c As an inseparable mixture. Yield and ratio determined by ¹H NMR.

Conclusion

As a conclusion, the high potential of diphenylborinic acid 2-aminoethyl ester as inducer of regioselective galactofuranosylation of various acceptors was confirmed. In this study we have validated the extension of Taylor's methodology from hexopyranosyl bromide to a 1,2-*trans* hexofuranosyl bromide unable to react in a pure S_N2 glycosylation pathway. When using silver oxide as promoter, only one regioisomer was formed as expected. High amount of orthoester however was formed when the *O*-6 or *C*-1 position of the acceptor possessed an electron-donating group. Silver triflate could be used instead but such an acidic catalyst destabilized the borinate adduct and the resulting regioselectivity dropped. The role of the substituents on the acceptor was partly explained thanks to *ab initio* calculation of the Fukui index of all borinate complexes. Electron-donating groups at primary and anomeric positions significantly increased the Fukui indexes and borinate adducts with high Fukui index on the equatorial oxygen generated the greater amount of orthoester. This is a confirmation that the electron-density of the substituent at the anomeric position of the acceptor can modulate the glycosylation reaction. Finally, despite these limitations, we managed to obtain quickly and efficiently galactofuranosyl containing disaccharides found in the glycocalix of pathogenic microorganisms. The minimum protecting group manipulation and the simplicity of the method represent an attractive alternative to biocatalysed process that still suffer from too strong specificity and low conversion yields.

Experimental Section

General Experimental Details

All reactions were carried out in oven-dried glassware. All reagents were purchased from commercial sources and were used without further purification unless noted. Dried acetonitrile, dichloromethane and THF were purchased sealed on molecular sieves. Unless

1
2
3 otherwise stated, all reactions were monitored by TLC on Silica Gel 60 F₂₅₄. TLC spots were
4
5 detected under 254 nm UV-light or by staining with cerium ammonium molybdate solution.
6
7 Column chromatography was performed on Silica Gel (25 or 50 μm). Optical rotations were
8
9 measured at 20 °C on a Perkin-Elmer 341 polarimeter. NMR spectra were recorded at 400
10
11 MHz for ¹H and 100 MHz for ¹³C. Chemical shifts are given in δ units (ppm) and referenced
12
13 to either CDCl₃ or CD₃OD. Coupling constants *J* were calculated in Hertz (Hz). Proton and
14
15 carbon NMR peaks were unambiguously assigned by COSY (double quantum filtered with
16
17 gradient pulse for selection), HSQC (gradient echo-anti echo selection and shape pulse) and
18
19 HMBC (echo-anti echo gradient selection, magnitude mode) correlation experiments. For
20
21 each isolated oligosaccharide, the reducing end (bearing *p*NP or alkyl chain) was quoted as
22
23 “a”, and the letter increased toward the non-reducing end (for example the sugar after was
24
25 quoted as “b”). High Resolution Masses were) were recorded in positive mode using direct
26
27 Electrospray ionization on a Waters Q-ToF 2 spectrometer.
28
29
30
31

32
33 **4-Nitrophenyl 6-*O*-*tert*-butyldimethylsilyl- α -D-mannopyranoside (2b):** To a solution of 4-
34
35 Nitrophenyl α -D-mannopyranoside **2a** (1.5 g, 4.98 mmol) in DMF (30 mL) were added
36
37 imidazole (1.02 g, 14.94 mmol), a catalytic amount of DMAP (30 mg, 0.25 mmol) followed
38
39 by TBSCl (901 mg, 5.98 mmol). The reaction mixture was stirred at room temperature until
40
41 no evolution was observed through TLC monitoring (8 h). The reaction mixture was diluted
42
43 into CH₂Cl₂ (100 mL) and washed with water (100 mL). The organic layer was washed twice
44
45 with a saturated aq NH₄Cl solution, water and brine. The resulting organic layer was dried
46
47 with MgSO₄, filtered and concentrated under reduced pressure. The remaining silane was
48
49 removed by submitting the crude material to vacuum during several hours. The 6-*O*-protected
50
51 mannopyranoside **2b** was obtained as a white solid (829 mg, 40%) and could be used without
52
53 further purification. $[\alpha]_D^{20} + 115$ (c 1, MeOH). ¹H NMR (CD₃OD): δ_H 8.20 (2H, d, *J* = 9.3 Hz,
54
55 H_{Ar}), 7.28 (2H, d, *J* = 9.3 Hz, H_{Ar}), 5.64 (1H, d, *J*_{1,2} = 1.8 Hz, H-1), 4.04 (1H, dd, *J*_{2,3} = 3.4
56
57
58
59
60

1
2
3 Hz, H-2), 3.92 (1H, dd, $J_{6,5} = 2$ Hz, $J_{6,6'} = 11.2$ Hz, H-6), 3.87 (1H, dd, $J_{3,4} = 9.3$ Hz, H-3),
4
5 3.74 (1H, dd, $J_{6',5} = 6.8$ Hz, H-6'), 3.65 (1H, app. t, $J_{4,5} = 9.5$ Hz, H-4), 3.50 (1H, ddd, H-5),
6
7 0.8 (9H, s, C(CH₃)₃), 0.02 (3H, s, OSi(CH₃)₂), 0.00 (3H, s, OSi(CH₃)₂). ¹³C NMR (CD₃OD):
8
9 δ_C 162.7 (C_{Ar}), 143.8 (C_{Ar}), 126.7 (C_{Ar}), 118.0 (C_{Ar}), 100.0 (C-1), 76.6 (C-5), 72.4 (C-3), 71.5
10 (C-2), 68.4 (C-4), 64.3 (C-6), 26.3 [SiC(CH₃)₃], 19.1 [SiC(CH₃)₃], -5.15 [OSi(CH₃)₂], -5.17
11 [OSi(CH₃)₂]. HRMS (ESI/Q-TOF) m/z: [M+Na]⁺ Calcd for C₁₈H₂₉NO₈SiNa 438.1560; Found
12 438.1560.
13
14
15
16
17
18

19 **General procedure for the regioselective acetylation of pyranosides:** A solution (0.1 M) of
20 4-nitrophenyl glycopyranoside in THF was heated to 45 °C until complete dissolution. Then
21 vinyl acetate (3 equiv.) and Novozym®435 were added (Lipase acrylic resin *Candida*
22 *antartica* from Novozymes) in a w/w ratio 1:1.2 [glycoside : immobilized enzyme]. The
23 reaction mixture was stirred at 45 °C until complete conversion of starting material (≈ 7 h).
24 The enzyme was filtered off and rinsed with MeOH. The resulting filtrate was then
25 concentrated under reduced pressure and purified by column chromatography on silica gel
26 (DCM/MeOH ratio 95:5).
27
28
29
30
31
32
33
34
35
36
37

38 **4-Nitrophenyl 6-O-acetyl- α -D-mannopyranoside (2c):** Synthesized according to general
39 procedure from *p*NP α -D-mannopyranoside **2a** (1.0 g, 3.32 mmol), vinyl acetate (918 μ L, 9.96
40 mmol) and Novozym®435 (1.2 g) to afford **2c** as a pale yellow solid (1.03 g, 90%). $[\alpha]_D^{20} +$
41 128 (c 1, MeOH). ¹H NMR (CD₃OD): δ_H 8.24 (2H, d, $^3J = 9.3$ Hz, H_{Ar}), 7.27 (2H, d, H_{Ar}),
42 5.63 (1H, d, $J_{1,2} = 1.7$ Hz, H-1), 4.33 (1H, dd, $J_{6,6'} = 11.8$ Hz, $J_{6a,5} = 2$ Hz, H-6), 4.19 (1H, dd,
43 $J_{6',5} = 6.4$, H-6'), 4.05 (1H, dd, $J_{2,3} = 3.4$ Hz, H-2), 3.88 (1H, dd, $J_{3,4} = 9$ Hz, H-3), 3.73 (1H,
44 app. t, $J_{4,5} = 9.8$ Hz, H-4), 3.61 (1H, ddd, H-5), 1.94 (3H, s, CH₃CO). ¹³C NMR (CD₃OD): δ_C
45 172.7 (CO), 162.6 (C_{Ar}), 144.0 (C_{Ar}), 126.7 (C_{Ar}), 117.9 (C_{Ar}), 100 (C-1); 73.5 (C-4), 72.2 (C-
46 3), 71.5 (C-2), 68.3 (C-5), 64.8 (C-6), 20.7 (CH₃CO). HRMS (ESI/Q-TOF) m/z: [M+Na]⁺
47 Calcd for C₁₄H₁₇NO₉Na 366.0801 ; Found 366.0797.
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Octyl 6-*O*-acetyl- α -D-mannopyranoside (4a):** Synthesized according to general procedure
4 from octyl α -D-mannopyranoside **3a**⁴⁰ (300 mg, 1 mmol), vinyl acetate (284 μ L, 3.31 mmol)
5 and Novozym[®]435 (400 mg) to afford **2c** as a colorless oil (305 mg, 90%). $[\alpha]_D^{20} + 43$ (c 1,
6 MeOH). ¹H NMR (CD₃OD): δ_H 4.70 (1H, d, $J_{1,2} = 1.6$ Hz, H-1), 4.39 (1H, dd, $J_{6,6'} = 11.7$ Hz,
7 $J_{6,5} = 2.0$ Hz, H-6), 4.20 (1H, dd, $J_{6',5} = 6.4$ Hz, H-6'), 3.79 (1H, dd, $J_{2,3} = 3.2$ Hz, H-2), 3.73–
8 3.65 (3H, m, H-5, H-3, OCH₂), 3.60 (1H, t, $J_{4,5} = 9.4$ Hz, H-4), 3.42 (1H, dt, $^2J = 9.6$ Hz, $^3J =$
9 6.3 Hz, OCH₂), 2.06 (3H, s, COCH₃), 1.66–1.54 (2H, m, OCH₂CH₂), 1.45–1.27 (10H, m,
10 (CH₂)₅CH₃), 0.91 (3H, t, $^3J = 6.8$ Hz, CH₂CH₃). ¹³C NMR (CD₃OD): δ_C 172.8 (CO), 101.7
11 (C-1), 72.6 (C-3), 72.1, 72.1 (C-2, C-5), 68.7, 68.7 (C-4, OCH₂), 65.3 (C-6), 33.0, 30.6, 30.5,
12 30.4, 27.4, 23.7[(CH₂)₅CH₃], 20.8 (COCH₃), 14.4 (CH₂CH₃). HRMS (ESI/Q-TOF) m/z:
13 [M+Na]⁺ Calcd for C₁₆H₃₀O₇Na 357.18837 ; Found 357.1882.

14
15
16
17
18
19
20
21
22
23
24
25
26
27
28 **Thiotolyl 6-*O*-acetyl- α -D-mannopyranoside (4b):** Synthesized according to general
29 procedure from thiotolyl α -D-mannopyranoside **3b**⁴¹ (780 mg, 2.7 mmol), vinyl acetate (750
30 μ L, 8.2 mmol) and Novozym[®]435 (1 g) to afford **4b** as a colorless oil (624 mg, 69%). $[\alpha]_D^{20}$
31 +244 (c 1.25, MeOH). ¹H NMR (CD₃OD): δ_H 7.40 (2H, d, $^3J = 8.1$ Hz, H_{Ar}), 7.14 (2H, d,
32 H_{Ar}), 5.35 (1H, d, $J_{1,2} = 1.5$ Hz, H-1), 4.43-4.35 (1H, m, H-6), 4.29-4.20 (2H, m, H-5, H-6'),
33 4.07 (1H, dd, $J_{2,3} = 2.9$ Hz, H-2), 3.72-3.64 (2H, m, H-3, H-4), 2.32 (3H, s, CH₃), 2.00 (3H, s,
34 COCH₃). ¹³C NMR (CD₃OD): δ_C 172.7 (CO), 139.0, 133.5, 131.7, 130.7 (C_{Ar}), 90.3 (C-1),
35 73.4 (C-2), 73.0, 72.9 (C-4, C-5), 69.0 (C-3), 65.0 (C-6), 21.1 (CH₃), 20.8 (COCH₃). HRMS
36 (ESI/Q-TOF) m/z: [M+Na]⁺ Calcd for C₁₅H₂₀O₆SNa 351.08728 ; Found 351.0872.

37
38
39
40
41
42
43
44
45
46
47
48
49 **4-Nitrophenyl 6-*O*-acetyl- β -D-galactopyranoside (12):** Synthesized according to general
50 procedure from *p*NP β -D-galactopyranoside **11** (100 mg, 0.3 mmol), vinyl acetate (100 μ L,
51 1mmol) and Novozym[®]435 (120 mg) to afford **12** as a colorless oil (56 mg, 50%). ¹H NMR
52 (CD₃OD+CDCl₃): δ_H 8.20 (2H, d, $^3J = 9.3$ Hz, H_{Ar}), 7.19 (2H, d, H_{Ar}), 4.99 (1H, d, $J_{1,2} = 7.7$
53 Hz, H-1), 4.34 (1H, dd, $J_{6,6'} = 11.5$ Hz, $J_{6,5} = 7.8$ Hz, H-6), 4.25 (1H, dd, $J_{6',5} = 4.5$ Hz, H-6'),
54
55
56
57
58
59
60

1
2
3 3.99–3.91 (1H, m, H-5), 3.90 (1H, dt, $J_{4,3} = 3.5$ Hz, $J_{4,5} = 0.9$ Hz, H-4), 3.85 (1H, dd, $J_{2,3} = 9.7$
4 Hz, H-2), 3.61 (1H, dd, H-3), 2.07 (3H, s, CH₃). ¹³C NMR (CD₃OD): δ_C 172.2 (CO), 163.4,
5 143.5, 126.3, 117.4 (C_{Ar}), 101.6 (C-1), 74.1 (C-3, C-5), 71.4 (C-2), 69.5 (C-4), 64.4 (C-6),
6 20.9 (CH₃). HRMS (ESI/Q-TOF) m/z: [M+Na]⁺ Calcd for C₁₄H₁₇NO₉Na 366.0801 ; Found
7 366.0804.
8
9

10
11
12
13
14 **4-Nitrophenyl 6-O-acetyl-2-deoxy-β-D-N-acetylgalactosamine (14)**: Synthesized according
15 to described procedure³⁸ from *p*NP β-D-*N*-acetylgalactosamine **13** (280 mg, 0.8 mmol), vinyl
16 acetate (10 mL) Novozym[®] 435 (350 mg) in a mixture of acetone/pyridine (29/21 mL) to
17 afford **14** as a white solid (161 mg, 51%). Spectroscopic data were in accordance with
18 previous report.
19
20
21
22
23
24
25

26
27 **General procedure for the 2-ADPB-assisted glycosidic coupling**: Bromide donor **1a**³⁰ (2
28 equiv.), acceptor (1 equiv.) and 2-aminoethyl diphenylborinate (2-DPBA, 1 equiv.) were
29 suspended in dry CH₃CN (40 mM) with activated 4 Å molecular sieves (100 mg / mL) and
30 under a nitrogen atmosphere. The mixture was stirred for 30 min and Ag₂O (1 equiv.) was
31 added. Alternatively, the mixture was protected from light and AgOTf (1 equiv.) was used.
32 After stirring at room temperature, when no evolution was observed through TLC monitoring,
33 the reaction mixture was diluted with EtOAc and filtered through a plug of Celite. In the case
34 of AgOTf-promoted reactions, a few drops of Et₃N were added to neutralize the reaction prior
35 to dilution and filtration. The filtrate was concentrated under reduced pressure and the
36 resulting crude material was purified by column chromatography on silica gel (cyclohexane/
37 ethyl acetate ratio 4:1).
38
39
40
41
42
43
44
45
46
47
48
49
50

51
52 **4-Nitrophenyl 2,3,5,6-tetra-O-benzoyl-β-D-galactofuranosyl-(1→3)-6-O-tert-**
53 **butyldimethylsilyl-α-D-mannopyranoside (5b)**: Synthesized according to general procedure
54 starting from 6-*O*-TBS-mannopyranoside **2b** (63 mg, 0.15 mmol), galactofuranosyl bromide
55
56
57
58
59
60

1
2
3 **1a** (200 mg, 0.30 mmol), 2-DPBA (34 mg, 0.15 mmol) and Ag₂O (35 mg, 0.15 mmol).
4
5 Reaction reached completion after 6 h. Purification by column chromatography on silica gel
6
7 afforded **5b** (70 mg, 46%) as a white solid. Further elution allowed isolating the
8
9 corresponding orthoester **6b** (37 mg, 24%).
10
11

12 **5b**: [α]_D²⁰ + 12 (c 1, CH₂Cl₂). ¹H NMR (CDCl₃): δ _H 8.19 (2H, d, *J* = 9.3 Hz, H_{Ar}), 8.10, 8.04,
13 7.99, 7.93 (8H, 4dd, *J* = 8.3 Hz, *J* = 1.2 Hz, H_{Ar}), 7.61-7.29 (12H, m, H_{Ar}), 7.15 (2H, d, H_{Ar}),
14 6.03-5.98 (1H, m, H-5b), 5.76 (1H, dd, *J*_{3b,4b} = 5.8 Hz, *J*_{3b,2b} = 2 Hz, H-3b), 5.70 (1H, d, *J*_{1a,2a}
15 = 1.5 Hz, H-1a), 5.55 (1H, bs, H-1b), 5.49 (1H, dd, *J*_{2b,1b} = 0.7 Hz, H-2b), 4.95 (1H, dd, *J*_{4b,5b}
16 = 3.6 Hz, H-4b), 4.80 (2H, d, *J*_{6b,5b} = 4.9 Hz, H-6b), 4.28 (1H, bs, H-2a), 4.14 (1H, dd, *J*_{3a,2a} =
17 3.3 Hz, *J*_{3a,4a} = 9.3 Hz, H-3a), 4.02 (1H, app. td, *J*_{4a,5a} = 9.6 Hz, *J*_{4a,OH} = 2.7 Hz, H-4), 3.87
18 (1H, dd, *J*_{6a,6'a} = 11 Hz, *J*_{6a,5a} = 4.2 Hz, H-6a), 3.81 (1H, dd, *J*_{6'a,5a} = 5.4 Hz, H-6'a), 3.65-3.58
19 (1H, m, H-5a), 3.17 (1H, d, OH), 2.94 (1H, d, *J*_{OH,2a} = 2.5 Hz, OH), 0.84 (9H, s, *t*Bu-Si), 0.04
20 [6H, s, OSi(CH₃)₂]. ¹³C NMR (CDCl₃): δ _C 166.3, 166.2, 165.7, 165.6 (COPh), 160.8, 142.6
21 (C_{pNP}), 133.8, 133.7, 133.4, 133.2, 130.2, 129.9, 129.8, 129.4, 129.3, 128.8, 128.5, 128.4
22 (C_{Ph}), 125.8, 116.5 (C_{pNP}), 103.8 (C-1b), 97.7 (C-1a), 83.1 (C-2b), 81.2 (C-4b), 77.3 (C-3a),
23 76.8 (C-3b), 73.0 (C-5a), 70.1 (C-5b), 67.5 (C-2a), 66.8 (C-4a), 63.6 (C-6a), 63.3 (C-6b), 25.8
24 [SiC(CH₃)₃], 18.2 [SiC(CH₃)₃], -5.5, -5.4 [OSi(CH₃)₂]. HRMS (ESI/Q-TOF) *m/z*: [M+Na]⁺
25
26 Calcd for C₅₂H₅₅NO₁₇SiNa 1016.3137 ; Found 1016.3134.
27
28

29
30 **6b**: [α]_D²⁰ + 65 (c 1, CH₂Cl₂). ¹H NMR (CDCl₃): δ _H 8.16 (2H, d, *J* = 9.3 Hz, H_{Ar}), 7.97, 7.93,
31 7.86, 7.76 (8H, 4dd, *J* = 8.5 Hz, *J* = 1.3 Hz, H_{Ar}), 7.61-7.30 (12H, m, H_{Ar}), 7.06 (2H, d, *J* =
32 9.3 Hz, H_{Ar}), 6.47 (1H, d, *J*_{1b,2b} = 4.4 Hz, H-1b), 5.56 (1H, dd, *J*_{3b,4b} = 3.5 Hz, *J*_{3b,2b} = 0.9 Hz,
33 H-3b), 5.47 (1H, d, *J*_{2a,1a} = 1.8 Hz, H-1a), 5.37-5.32 (1H, m, H-5b), 5.30 (1H, dd, H-2b), 4.69
34 (1H, dd, *J*_{4b,5b} = 8.0 Hz, H-4b), 4.56 (1H, dd, *J*_{6b,6'b} = 12.5 Hz, *J*_{6b,5b} = 3.9 Hz, H-6b), 4.38 (1H,
35 dd, *J*_{6'b,5b} = 4.9 Hz, H-6'b), 4.08 (1H, dd, *J*_{3a,2a} = 3.3 Hz, *J*_{3a,4a} = 9.4 Hz, H-3a), 3.93 (1H,
36 app. td, *J*_{4a,5a} = 9.5 Hz, *J*_{4a,OH} = 2 Hz, H-4a), 3.78 (2H, d, *J*_{6a,5a} = 4.3 Hz, H-6a), 3.64 (1H, br s,
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

H-2a), 3.58-3.53 (1H, m, H-5a), 3.04 (1H, d, OH), 2.37(1H, d, $J_{\text{OH},2a} = 2.8$ Hz, OH), 0.83 (9H, s, *t*Bu-Si), 0.02 [6H, s, OSi(CH₃)₂]. ¹³C NMR (CDCl₃): δ_C 165.6, 165.3, 165.2 (COPh), 160.8, 142.6 (C_{pNP}), 136.1, 133.7, 133.4, 133.2, 133.1, 130.0, 129.9, 129.8, 129.6, 129.5, 129.4, 128.6, 128.5, 128.3, 128.2, 125.8 (C_{Ph}), 125.7 (C_{pNP}), 123.3 (PhCO₃), 116.3 (C_{pNP}), 105.3 (C-1b), 97.4 (C-1a), 85.7 (C-2b), 83.9 (C-4b), 76.8 (C-3b), 73.7 (C-3a), 72.7 (C-5a), 71.2 (C-5b), 69.0 (C-2a), 67.3 (C-4a), 64.0 (C-6a), 62.8 (C-6b), 25.8 [SiC(CH₃)₃], 18.3 [SiC(CH₃)₃], -5.5, -5.6 [OSi(CH₃)₂]. HRMS (ESI/Q-TOF) m/z: [M+Na]⁺ Calcd for C₅₂H₅₅NO₁₇SiNa 1016.3137 ; Found 1016.3130.

4-Nitrophenyl 2,3,5,6-tetra-O-benzoyl-β-D-galactofuranosyl-(1→3)-6-O-acetyl-α-D-mannopyranoside (5c): Synthesized according to general procedure starting from 6-O-Ac-mannopyranoside **2c** (52 mg, 0.15 mmol), galactofuranosyl bromide **1a** (200 mg, 0.30 mmol), 2-DPBA (34 mg, 0.15 mmol) and Ag₂O (35 mg, 0.15 mmol). Reaction reached completion after 2 h. Purification by column chromatography on silica gel afforded **5c** (119 mg, 85%) as a white solid. $[\alpha]_{\text{D}}^{20} + 37.5$ (c 0.8, CH₂Cl₂). ¹H NMR (CDCl₃): δ_H 8.20 (2H, d, $J = 9.3$ Hz, H_{Ar}), 8.11, 8.02, 7.99, 7.93 (8H, 4 dd, $J = 1.3$ Hz, $J = 8.4$ Hz, H_{Ar}), 7.60-7.32 (12H, m, H_{Ar}), 7.14 (2H, d, H_{Ar}), 5.99-5.94 (1H, m, H-5b), 5.77 (1H, dd, $J_{3b,2b} = 2.2$ Hz, $J_{3b,4b} = 6.0$ Hz, H-3b), 5.71 (1H, d, $J_{1a,2a} = 1.5$ Hz, H-1a), 5.54 (1H, br s, H-1b), 5.49 (1H, dd, $J_{2b,1b} = 0.7$ Hz, H-2b), 4.95 (1H, dd, $J_{4b,5b} = 3.7$ Hz, H-4b), 4.83 (1H, dd, $J_{6b,6'b} = 11.9$ Hz, $J_{6b,5b} = 4.8$ Hz, H-6b), 4.78 (1H, dd, $J_{6'b,5b} = 6.1$ Hz, H-6'b), 4.39 (1H, dd, $J_{6a,5a} = 5.2$ Hz, $J_{6a,6'a} = 12.2$ Hz, H-6a), 4.31 (1H, br s, H-2a), 4.27 (1H, dd, $J_{6'a,5a} = 2.2$ Hz, H-6'a), 4.13 (1H, dd, $J_{3a,2a} = 3.3$ Hz, $J_{3a,4a} = 9.3$ Hz, H-3), 3.96 (1H, app. td, $J_{4a,\text{OH}} = 3.4$ Hz, $J_{4a,5a} = 9.7$ Hz, H-4a), 3.74 (1H, ddd, H-5a), 3.24 (1H, d, OH), 3.08 (1H, d, $J_{2a,\text{OH}} = 1.9$ Hz, OH), 2.04 (3H, s, CH₃CO). ¹³C NMR (CDCl₃): δ_C 171.3 (COCH₃), 166.3, 165.6 (COPh), 160.6, 142.8, 133.8, 133.7, 133.5, 133.3, 130.0, 129.9, 129.8, 129.4, 129.3, 128.7, 128.6, 128.5, 128.4, 125.7, 116.4 (C_{Ar}), 103.9 (C-1b), 97.8 (C-1a), 83.3 (C-2b), 81.0 (C-4b), 77.0 (C-3a), 76.7 (C-3b), 71.7 (C-5a), 70.0 (C-5b), 67.6 (C-2a), 65.3

(C-4a), 63.1, 63.0 (C-6a, C-6b), 20.8 (CH₃CO). HRMS (ESI/Q-TOF) m/z: [M+Na]⁺ Calcd for C₄₈H₄₃NO₁₈Na 944.23723 ; Found 944.2391.

Octyl 2,3,5,6-*O*-benzoyl-β-D-galactofuranosyl)-(1→3)-6-*O*-acetyl-α-D-mannopyranoside

(8a): Synthesized according to general procedure starting from 6-*O*-Ac-mannopyranoside **4a** (51 mg, 0.15 mmol), galactofuranosyl bromide **1a** (200 mg, 0.30 mmol), 2-DPBA (34 mg, 0.15 mmol) and Ag₂O (35 mg, 0.15 mmol). Reaction reached completion after 2 h. Purification by column chromatography on silica gel afforded **8a** (56 mg, 40%) as a white solid. Further elution allowed isolating the corresponding orthoester **9a** (68 mg, 49%).

Alternative protocol using **4a** (44 mg, 0.13 mmol), **1a** (176 mg, 0.27 mmol), 2-DPBA (30 mg, 0.13 mmol) and AgOTf (34 mg, 0.13 mmol) as promoter gave **8a** (70 mg, 57%) in mixture with the octyl β-D-Galf-(1→4)-D-Manp regioisomer (ratio 4:1).

8a: [α]_D²⁰ + 6 (c 1.5, CHCl₃). ¹H NMR (CDCl₃): δ_H 8.13-7.88 (8H, m, H_{Ar}), 7.62-7.47 (4H, m, H_{Ar}), 7.46-7.28 (8H, m, H_{Ar}), 5.96 (1H, dt, $J_{5b,6'b}$ = 6.2 Hz, $J_{5b,6b}$ = 4.7 Hz, $J_{5b,4b}$ = 3.8 Hz, H-5b), 5.73 (1H, dd, $J_{3b,4b}$ = 5.8 Hz, $J_{3b,2b}$ = 1.9 Hz, H-3b), 5.51-5.46 (2H, m, H-1b, H-2b), 4.91 (1H, dd, H-4b), 4.89 (1H, d, $J_{1a,2a}$ = 1.6 Hz, H-1a), 4.80 (1H, dd, $J_{6b,6'b}$ = 11.9 Hz, H-6b), 4.74 (1H, dd, H-6'b), 4.40 (1H, dd, $J_{6a,6'a}$ = 11.9 Hz, $J_{6a,5a}$ = 4.7 Hz, H-6a), 4.36 (1H, dd, $J_{6'a,5a}$ = 2.8 Hz, H-6'a), 4.07 (1H, dd, $J_{2a,3a}$ = 3.3 Hz, H-2a), 3.95 (1H, dd, $J_{3a,4a}$ = 9.2 Hz, H-3a), 3.86 (1H, dd, $J_{4a,5a}$ = 9.7 Hz, H-4a), 3.77 (1H, ddd, H-5a), 3.66 (1H, dt, 2J = 9.7 Hz, 3J = 6.8 Hz, OCH₂), 3.42 (1H, dt, 3J = 6.6 Hz, OCH₂), 2.11 (3H, s, COCH₃) 1.56 (2H, m, OCH₂CH₂), 1.36–1.20 (10H, m, (CH₂)₅CH₃), 0.87 (3H, t, 3J = 6.9, CH₂CH₃). ¹³C NMR (CDCl₃): δ_C 171.5, 166.4, 166.2, 165.8, 165.7 (CO), 134.8, 133.8, 133.5, 133.3, 130.1, 130.1, 130.0, 129.9, 129.6, 129.5, 128.9, 128.7, 128.6, 128.6, 128.5, 128.0 (C_{Ar}), 104.4 (C-1b), 99.5 (C-1a), 83.1 (C-2b), 81.2 (C-4b), 78.8 (C-3a), 77.0 (C-3b), 70.4 (C-5a), 70.3 (C-5b), 68.6 (C-2a), 68.1 (OCH₂), 66.0 (C-4a), 63.8 (C-6a), 63.2 (C-6b), 32.0, 29.5, 29.5, 29.3, 26.2, 22.8 [(CH₂)₆CH₃],

21.1 (COCH₃), 14.2 (CH₂CH₃). HRMS (ESI/Q-TOF) m/z: [M+Na]⁺ Calcd for C₅₀H₅₆O₁₆Na 935.34606 ; Found 935.3467.

9a: ¹H NMR (CDCl₃): δ_H 7.97-7.91 (2H, m, H_{Ar}), 7.91- 7.83 (4H, m, H_{Ar}), 7.75-7.70 (2H, m, H_{Ar}), 7.60- 7.54 (1H, m, H_{Ar}), 7.53-7.46 (2H, m, H_{Ar}), 7.42-7.36 (5H, m, H_{Ar}), 7.36-7.28 (4H, m, H_{Ar}), 6.36 (1H, d, *J*_{1b,2b} = 4.4 Hz, H-1b), 5.51 (1H, dd, *J*_{3b,4b} = 4.2 Hz, *J*_{3b,2b} = 1.5 Hz, H-3b), 5.28 (1H, ddd, *J*_{5b,4b} = 7.6 Hz, *J*_{5b,6'b} = 5.0 Hz, *J*_{5b,6b} = 3.9 Hz, H-5b), 5.23 (1H, dd, H-2b), 4.71 (1H, d, *J*_{1a,2a} = 1.7 Hz, H-1a), 4.62 (1H, dd, H-4b), 4.51 (1H, dd, *J*_{6b,6'b} = 12.4 Hz, H-6b), 4.42 (1H, dd, *J*_{6a,6'a} = 12.1 Hz, *J*_{6a,5a} = 4.6 Hz, H-6a), 4.33 (1H, dd, H-6'b), 4.27 (1H, dd, *J*_{6'a,5a} = 2.1 Hz, H-6'a), 3.90 (1H, dd, *J*_{3a,4a} = 8.8 Hz, *J*_{3a,2a} = 3.3 Hz, H-3a), 3.79-3.67 (2H, m, H-4a, H5a), 3.63-3.55 (2H, m, H-2a, OCH₂), 3.33 (1H, dt, ²*J* = 9.7 Hz, ³*J* = 6.6 Hz, OCH₂), 2.87 (1H, d, *J*_{OH,4a} = 2.8 Hz, OH), 2.17 (1H, d, *J*_{OH,2a} = 3.2 Hz, OH), 2.09 (3H, s, COCH₃), 1.56-1.46 (2H, m, OCH₂CH₂), 1.31-1.23 (10H, m, (CH₂)₅CH₃), 0.88 (3H, t, ³*J* = 6.9 Hz, (CH₂)₅CH₃). ¹³C NMR (CDCl₃): δ_C 171.7 (COCH₃), 165.8, 165.4, 165.3 (COPh), 136.6, 133.8, 133.2, 133.2, 130.1, 130.0, 129.9, 129.8, 129.6, 128.7, 128.6, 128.5, 128.4, 126.2 (C_{Ar}), 123.9 (PhCO₃), 105.1 (C-1b), 99.3 (C-1a), 86.0 (C-2b), 83.1 (C-4b), 76.7 (C-3b), 74.5 (C-3a), 71.2 (C-5b), 70.6 (C-5a), 70.2 (C-2a), 68.0 (OCH₂), 65.6 (C-4a), 63.7 (C-6a), 62.9 (C-6b), 31.9, 29.4, 29.4, 29.4, 26.2, 22.8 [(CH₂)₆CH₃], 21.0 (COCH₃), 14.2 [(CH₂)₆CH₃]. HRMS (ESI/Q-TOF) m/z: [M+Na]⁺ Calcd for C₅₀H₅₆O₁₆Na 935.34606 ; Found 935.3465.

Thiotolyl 2,3,5,6-*O*-benzoyl-β-D-galactofuranosyl-(1→3)-6-*O*-acetyl-α-D-mannopyranoside (8b): Synthesized according to general procedure starting from thiotolyl 6-*O*-Ac-mannopyranoside **4b** (50 mg, 0.15 mmol), galactofuranosyl bromide **1a** (200 mg, 0.30 mmol), 2-DPBA (34 mg, 0.15 mmol) and Ag₂O (35 mg, 0.15 mmol). Reaction reached completion after 2 h. Purification by column chromatography on silica gel afforded **8b** (131 mg, 96%) as a white solid.

Alternative protocol using **4b** (50 mg, 0.15 mmol), **1a** (200 mg, 0.30 mmol), 2-DPBA (34 mg, 0.14 mmol) and AgOTf (39 mg, 0.15 mmol) as promoter gave **8b** (94 mg, 69%).

8b: $[\alpha]_D^{20} + 60$ (c 1.15, CH₂Cl₂). ¹H NMR (CDCl₃): δ_H 8.11 (2H, dd, ³*J* = 8.4 Hz, ⁴*J* = 1.3 Hz, H_{Ar}), 8.02 (4H, dd, ³*J* = 8.4 Hz, ⁴*J* = 1.3 Hz, H_{Ar}), 7.93 (2H, dd, ³*J* = 8.4 Hz, ⁴*J* = 1.3 Hz, H_{Ar}), 7.61-7.51 (4H, m, H_{Ar}), 7.46-7.31 (10H, m, H_{Ar}), 7.12 (2H, d, ³*J* = 8.0 Hz, H_{Tol}), 5.94 (1H, td, *J*_{5b,6b} = 5.3 Hz, *J*_{5b,4b} = 3.6 Hz, H-5b), 5.73 (1H, dd, *J*_{3b,4b} = 5.9 Hz, *J*_{3b,2b} = 2.2 Hz, H-3b), 5.54 (1H, d, *J*_{1a,2a} = 1.4 Hz, H-1a), 5.48 (1H, d, *J*_{1b,2b} = 0.8 Hz, H-1b), 5.48 (1H, dd, H-2b), 4.92 (1H, dd, H-4b), 4.80 (2H, d, H-6b), 4.41 (1H, dd, *J*_{6a,6'a} = 12.1 Hz, *J*_{6a,5a} = 5.9 Hz, H-6a), 4.37-4.30 (3H, m, H-2a, H-5a, H-6'a), 3.98-3.88 (2H, m, H-3a, H-4a), 3.19 (1H, d, *J*_{OH,4a} = 3.8 Hz, OH), 2.33 (3H, s, CH₃), 2.07 (3H, s, COCH₃). ¹³C NMR (CDCl₃): δ_C 171.4, 166.5, 166.2, 165.8, 165.7 (CO), 138.1, 133.9, 133.6, 133.4, 132.5, 130.1, 130.0, 129.6, 129.5, 128.9, 128.7, 128.6 (C_{Ar}), 104.1 (C-1b), 87.8 (C-1a), 83.2 (C-2b), 81.4 (C-4b), 78.3 (C-3a), 77.0 (C-3b), 71.4 (C-5a), 70.2 (C-5b), 69.6 (C-2a), 66.4 (C-4a), 63.8 (C-6a), 63.2 (C-6b), 21.3 (CH₃), 21.0 (COCH₃). HRMS (ESI/Q-TOF) *m/z*: [M+Na]⁺ Calcd for C₄₉H₄₆O₁₅SNa 929.24496 ; Found 929.2455.

***p*-Nitrophenyl (2, 3, 5, 6-*O*-tetrabenzoyl- β -D-galactofuranosyl)-(1 \rightarrow 3)-6-*O*-acetyl- β -D-galactopyranoside (17)**: Synthesized according to general procedure starting from *p*NP 6-*O*-Ac-galactopyranoside **12** (52 mg, 0.15 mmol), galactofuranosyl bromide **1a** (200 mg, 0.30 mmol), 2-DPBA (34 mg, 0.15 mmol) and Ag₂O (35 mg, 0.15 mmol). Reaction reached completion after 2 h. Purification by column chromatography on silica gel afforded **17** (121 mg, 86%) as a white solid. $[\alpha]_D^{20} - 26.5$ (c 1, CHCl₃). ¹H NMR (CDCl₃): δ_H 8.20 (2H, d, *J* = 9.4 Hz, H_{*p*NP}), 8.12-8.06 (2H, m, H_{Bz}), 8.04-7.97 (4H, m, H_{Bz}), 7.95-7.89 (2H, m, H_{Bz}), 7.62-7.51 (3H, m, H_{Bz}), 7.47-7.29 (9H, m, H_{Bz}), 7.12 (2H, d, H_{*p*NP}), 5.97 (1H, ddd, *J*_{5b,6'b} = 6.3 Hz, *J*_{5b,6'b} = 5.0 Hz, *J*_{5b,4b} = 3.8 Hz, H-5b), 5.75 (1H, dd, *J*_{3b,4b} = 5.8 Hz, *J*_{3b,2b} = 2.2 Hz, H-3b), 5.69 (1H, d, *J*_{1b,2b} = 0.9 Hz H-1b), 5.56 (1H, dd, H-2b), 4.99 (1H, d, *J*_{1a,2a} = 7.8 Hz, H-1a), 4.83 (1H, dd,

1
2
3 $J_{6b,6'b} = 11.8$, H-6b), 4.80 (1H, dd, H-4b), 4.71 (1H, dd, H-6'b), 4.34 (1H, dd, $J_{6a,6'a} = 11.7$ Hz,
4
5 $J_{6a,5a} = 7.6$ Hz, H-6a), 4.24 (1H, dd, $J_{6'a,5a} = 4.8$ Hz, H-6'a), 4.22 (1H, dd, $J_{2a,3a} = 9.4$ Hz, H-
6
7 2a), 4.10 (1H, dd, $J_{4a,3a} = 3.4$ Hz, $J_{4a,5a} = 1.1$ Hz, H-4a), 3.86 (1H, ddd, H-5a), 3.79 (1H, dd,
8
9 H-3a), 2.08 (3H, s, CH₃). ¹³C NMR (CDCl₃): δ_C 170.8, 166.3, 166.3, 165.8, 165.7 (COPh),
10
11 161.8 (C_{pNP}), 142.9 (C_{pNP}), 133.9, 133.6, 133.5, 130.1, 130.0, 129.9, 129.4, 128.7, 128.6,
12
13 128.5 (C_{Bz}), 125.7 (C_{pNP}), 116.7 (C_{pNP}), 107.9 (C-1b), 100.2 (C-1a), 83.1 (C-2b), 81.6 (C-4b),
14
15 80.7 (C-3a), 77.0 (C-3b), 72.9 (C-5a), 70.2 (C-2a, C-5b), 68.5 (C-4a), 63.0 (C-6a, C-6b), 20.9
16
17 (CH₃). HRMS (ESI/Q-TOF) m/z: [M+Na]⁺ Calcd for C₄₈H₄₃NO₁₈Na 944.23723 ; Found
18
19 944.2368.
20
21

22
23
24 ***p*-Nitrophenyl (2, 3, 5, 6-tetra-*O*-benzoyl-β-D-galactofuranosyl)-(1→3)-2-acetamido-6-*O*-**
25
26 **acetyl-2-deoxy-β-D-galactopyranoside (18):** Synthesized according to general procedure
27
28 starting from *p*NP 6-*O*-acetyl-β-D-*N*-acetylgalactosamine **14** (58 mg, 0.15 mmol),
29
30 galactofuranosyl bromide **1a** (200 mg, 0.30 mmol), 2-DPBA (34 mg, 0.15 mmol) and Ag₂O
31
32 (35 mg, 0.15 mmol). Reaction reached completion after 2 h. Purification by column
33
34 chromatography on silica gel afforded **18** (14 mg, 10%) as a light brown solid. Further elution
35
36 allowed isolating the corresponding orthoester **18'** (54 mg, 37%).
37
38

39
40 Alternative protocol using **14** (58 mg, 0.15 mmol), **1a** (200 mg, 0.30 mmol), 2-DPBA (34 mg,
41
42 0.15 mmol) and AgOTf (39 mg, 0.15 mmol) as promoter gave **18** (80 mg, 55%) in mixture
43
44 with the *p*NP β-D-Galf-(1→4)-D-GalNHAc regioisomer (ratio 4:1).
45
46

47
48 **18:** ¹H NMR (CD₃OD+CDCl₃): δ_H 8.15 (2H, d, ³*J* = 9.2 Hz, H_{pNP}), 8.10-8.03 (2H, m, H_{Bz}),
49
50 8.02-7.93 (4H, m, H_{Bz}), 7.87-7.81 (2H, m, H_{Bz}), 7.57-7.50 (3H, m, H_{Bz}), 7.44-7.27 (9H, m,
51
52 H_{Bz}), 7.06 (2H, d, H_{pNP}), 5.95 (1H, ddd, $J_{5b,6'b} = 6.7$ Hz, $J_{5b,6b} = 4.4$ Hz, $J_{5b,4b} = 4.0$ Hz, H-5b),
53
54 5.68 (1H, d, $J_{1a,2a} = 8.2$ Hz, H-1a), 5.66 (1H, dd, $J_{3b,4b} = 5.4$ Hz, $J_{3b,2b} = 1.9$ Hz, H-3b), 5.43
55
56 (1H, d, H-2b), 5.37 (1H, s, H-1b), 4.84 (1H, dd, H-4b), 4.76 (1H, dd, $J_{6b,6'b} = 11.8$ Hz, H-6b),
57
58
59
60

4.67 (1H, dd, H-6'b), 4.49 (1H, dd, $J_{3a,2a} = 10.8$ Hz, $J_{3a,4a} = 3.3$ Hz, H-3a), 4.30 (1H, dd, $J_{6a,6'a} = 11.7$ Hz, $J_{6a,5a} = 7.9$ Hz, H-6a), 4.16 (1H, dd, $J_{6'a,5a} = 4.5$ Hz, H-6'a), 4.09 (1H, d, H-4a), 3.89 (1H, dd, H-5a), 3.80 (1H, dd, H-2a), 2.03 (3H, s, CH₃), 1.93 (3H, s, CH₃). ¹³C NMR (CD₃OD+CDCl₃): δ_C 172.4, 171.0 (COCH₃), 166.4, 166.2, 165.9, 165.9 (COPh), 161.9 (C_{pNP}), 142.8 (C_{pNP}), 133.9, 133.6, 133.5, 130.1, 130.0, 129.9, 129.8, 129.4, 128.7, 128.6, 128.5 (C_{Bz}), 125.7 (C_{pNP}), 116.7 (C_{pNP}), 107.9 (C-1b), 97.0 (C-1a), 83.0 (C-2b), 81.2 (C-4b), 77.4 (C-3b), 76.8 (C-3a), 72.8 (C-5a), 70.3 (C-5b), 68.2 (C-4a), 63.3 (C-6a, C-6b), 53.4 (C-2a), 23.3, 20.8 (COCH₃). HRMS (ESI/Q-TOF) m/z: [M+Na]⁺ Calcd for C₅₀H₄₆N₂O₁₈Na 985.26378 ; Found 985.2646.

18': ¹H NMR (CDCl₃): δ_H 8.14 (2H, d, ³J = 9.3 Hz, H_{pNP}), 7.93-7.88 (2H, m, H_{Bz}), 7.86-7.80 (4H, m, H_{Bz}), 7.73-7.68 (2H, m, H_{Bz}), 7.59-7.46 (3H, m, H_{Bz}), 7.43-7.27 (9H, m, H_{Bz}), 7.04 (2H, d, H_{pNP}), 6.21 (1H, d, $J_{1b,2b} = 4.3$ Hz, H-1b), 5.84 (1H, d, $J_{1a,2a} = 8.3$ Hz, H-1a), 5.76 (1H, d, $J = 7.0$, NH), 5.40 (1H, dd, $J_{3b,4b} = 5.4$ Hz, $J_{3b,2b} = 1.8$ Hz, H-3b), 5.19 (1H, ddd, $J_{5b,4b} = 7.0$ Hz, $J_{5b,6'b} = 5.3$ Hz, $J_{5b,6b} = 3.7$ Hz, H-5b), 5.10 (1H, dd, H-2b), 4.63 (1H, dd, $J_{3a,2a} = 10.6$ Hz, $J_{3a,4a} = 3.0$ Hz, H-3a), 4.51 (1H, dd, H-4b), 4.42 (1H, dd, $J_{6b,6'b} = 12.4$ Hz, H-6b), 4.32 (2H, d, $J_{6a,5a} = 6.2$ Hz, H-6a), 4.24 (1H, dd, H-6'b), 4.10 (1H, t, $J_{4a,3a} = J_{4a,OH} = 3.0$ Hz, H-4a), 3.92 (1H, t, H-5a), 3.54 (1H, ddd, $J_{2a,NH} = 7.0$ Hz, H-2a), 2.46 (1H, d, OH), 2.07 (3H, s, OCOCH₃), 1.98 (3H, s, NHCOCH₃). ¹³C NMR (CDCl₃): δ_C 171.9 (NHCO), 170.9 (OCO), 165.8, 165.4 (COPh), 161.9 (C_{pNP}), 142.9 (C_{pNP}), 137.4, 133.9, 133.3, 133.2, 130.2, 129.9, 129.8, 129.5, 128.7, 128.6, 128.5, 128.4, 126.2 (C_{Ar}), 125.8 (C_{pNP}), 124.8 (PhCO₃), 116.7 (C_{pNP}), 104.5 (C-1b), 96.6 (C-1a), 86.4 (C-2b), 81.2 (C-4b), 76.4 (C-3b), 72.7 (C-5a), 71.0 (C-5b), 70.0 (C-3a), 68.2 (C-4a), 63.2 (C-6a), 62.7 (C-6b), 53.9 (C-2a), 24.0 (NHCOCH₃), 21.0 (OCOCH₃). HRMS (ESI/Q-TOF) m/z: [M+Na]⁺ Calcd for C₅₀H₄₆N₂O₁₈Na 985.26378 ; Found 985.2632.

***p*-Nitrophenyl (2, 3, 5, 6-tetra-*O*-benzoyl-β-D-galactofuranosyl)-(1→3)-α-L-rhamnopyranoside (19)**: Synthesized according to general procedure starting from *p*NP α-L-

1
2
3 rhamnopyranoside **15** (43 mg, 0.15 mmol), galactofuranosyl bromide **1a** (200 mg, 0.30
4 mmol), 2-DPBA (34 mg, 0.15 mmol) and Ag₂O (35 mg, 0.15 mmol). Reaction reached
5 completion after 2 h. Purification by column chromatography on silica gel afforded **19** (58
6 mg, 45%) as a light brown foam. Further elution allowed isolating the corresponding
7 orthoester **19'** (43 mg, 33%).
8
9

10
11
12
13
14 Alternative protocol using **15** (43 mg, 0.15 mmol), **1a** (200 mg, 0.30 mmol), 2-DPBA (34 mg,
15 0.15 mmol) and AgOTf (39 mg, 0.15 mmol) as promoter gave **19** (77 mg, 59%) in mixture
16 with the *p*NP β-D-Galf-(1→4)-L-Rhap regioisomer (ratio 9:1).
17
18
19

20
21
22 **19**: [α]_D²⁰ -90 (c 0.8, CHCl₃). ¹H NMR (CDCl₃): δ_H 8.20 (2H, d, ³*J* = 9.3 Hz, H_{*p*NP}), 8.10 (2H,
23 dd, ³*J* = 8.4 Hz, ⁴*J* = 1.3 Hz, H_{Bz}), 8.05-7.90 (6H, m, H_{Bz}), 7.62-7.48 (4H, m, H_{Bz}), 7.47-7.40
24 (2H, m, H_{Bz}), 7.39-7.31 (6H, m, H_{Bz}), 7.11 (2H, d, H_{*p*NP}), 5.94 (1H, ddd, *J*_{5b,6'b} = 6.2 Hz, *J*_{5b,6b}
25 = 5.6 Hz, *J*_{5b,4b} = 3.5 Hz, H-5b), 5.78 (1H, dd, *J*_{3b,4b} = 6.2 Hz, *J*_{3b,2b} = 2.7 Hz, H-3b), 5.65 (1H,
26 d, *J*_{1b,2b} = 1.1 Hz, H-1b), 5.54 (1H, dd, H-2b), 5.49 (1H, d, *J*_{1a,2a} = 1.9 Hz, H-1a), 4.87 (1H, dd,
27 *J*_{6b,6'b} = 11.8 Hz, H-6b), 4.84 (1H, dd, H-4b), 4.69 (1H, dd, H-6'b), 4.26 (1H, dd, *J*_{2a,3a} = 3.4
28 Hz, H-2a), 4.05 (1H, dd, *J*_{3a,4a} = 9.3 Hz, H-3a), 3.81 (1H, t, *J*_{4a,3a} = *J*_{4a,5a} = 9.3 Hz, H-4a), 3.71
29 (1H, qd, *J*_{5a,CH₃} = 6.2 Hz, H-5a), 3.12 (1H, s, OH), 2.86 (1H, s, OH), 1.31 (3H, d, CH₃). ¹³C
30 NMR (CDCl₃): δ_C 166.6, 166.5, 165.8, 165.7 (COPh), 161.0 (C_{*p*NP}), 142.7 (C_{*p*NP}), 134.9,
31 134.0, 133.9, 133.7, 133.5, 130.2, 130.1, 130.0, 129.9, 129.4, 128.7, 128.7, 128.7, 128.6,
32 128.5, 128.1 (CPh), 125.9 (C_{*p*NP}), 116.4 (C_{*p*NP}), 108.6 (C-1b), 97.8 (C-1a), 83.9 (C-2b), 81.0
33 (C-3a,C-4b), 76.7 (C-3b), 71.3 (C-4a), 70.3 (C-2a), 70.1 (C-5b), 69.4 (C-5a), 63.0 (C-6b),
34 17.8. (CH₃). HRMS (ESI/Q-TOF) *m/z*: [M+Na]⁺ Calcd for C₄₆H₄₁NO₁₆Na 886.23175 ; Found
35 886.2322.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52

53
54 **19'**: ¹H NMR (CDCl₃): δ_H 8.14 (2H, d, ³*J* = 9.2 Hz, H_{*p*NP}), 7.96-7.91 (2H, m, H_{Bz}), 7.89-7.84
55 (4H, m, H_{Bz}), 7.79-7.73 (2H, m, H_{Bz}), 7.61-7.55 (1H, m, H_{Bz}), 7.54-7.48 (2H, m, H_{Bz}), 7.44-
56
57
58
59
60

7.30 (9H, m, H_{Bz}), 7.05 (2H, d, H_{pNP}), 6.36 (1H, d, $J_{1b,2b} = 4.2$ Hz, H-1b), 5.53-5.49 (2H, m, H-1a, H-3b), 5.28-5.23 (1H, m, H-5b), 5.25 (1H, dd, $J_{2b,3b} = 1.5$ Hz, H-2b), 4.63 (1H, dd, $J_{4b,3b} = 7.5$ Hz, $J_{4b,5b} = 4.6$ Hz, H-4b), 4.51 (1H, dd, $J_{6b,6'b} = 12.5$ Hz, $J_{6b,5b} = 3.7$ Hz, H-6b), 4.32 (1H, dd, $J_{6'b,5b} = 5.3$ Hz, H-6'b), 4.06 (1H, t, $J_{OH,2a} = J_{2a,3a} = 3.1$ Hz, H-2a), 4.00 (1H, dd, $J_{3a,4a} = 8.8$ Hz, H-3a), 3.69-3.57 (2H, m, H-4a, H-5a), 2.59 (1H, d, OH), 2.52 (1H, d, $J_{OH,4a} = 2.4$ Hz, OH), 1.26 (3H, d, $J_{CH_3,5a} = 1.0$ Hz, CH₃). ¹³C NMR (CDCl₃): δ_C 165.8, 165.5, 165.4 (COPh), 161.0 (C_{pNP}), 142.7 (C_{pNP}), 136.6, 134.0, 133.3, 130.1, 129.9, 129.8, 128.7, 128.6, 128.5, 128.4, 126.2 (C_{Bz}), 125.9 (C_{pNP}), 124.3 (PhCO₃), 116.3 (C_{pNP}), 104.8 (C-1b), 97.7 (C-1a), 86.2 (C-2b), 82.4 (C-4b), 76.6 (C-3b), 74.4 (C-3a), 71.1 (C-5b), 70.5 (C-4a), 70.0 (C-5a), 69.7 (C-2a), 62.9 (C-6b), 17.8 (CH₃). HRMS (ESI/Q-TOF) m/z: [M+Na]⁺ Calcd for C₄₆H₄₁NO₁₆Na 886.23175 ; Found 886.2318.

4-Nitrophenyl 2,3,5,6-tetra-O-benzoyl-β-D-galactofuranosyl-(1→6)-β-D-galactofuranoside (20): Synthesized according to general procedure starting from pNP β-D-galactofuranoside **16** (20 mg, 67 μmol), galactofuranosyl bromide **1a** (88 mg, 0.13 mmol), 2-DPBA (15 mg, 67 μmol) and Ag₂O (15 mg, 67 μmol). Reaction reached completion after 2 h. Purification by column chromatography on silica gel afforded **20** (7 mg, 12%) as a white solid. Further elution allowed isolating the corresponding orthoester **20'** (35 mg, 56%).

Alternative protocol using **16** (20 mg, 67 μmol), **1a** (88 mg, 0.13 mmol), 2-DPBA (15 mg, 65 μmol) and AgOTf (16 mg, 65 μmol) as promoter yielded a 7:1 inseparable mixture of **20** and pNP β-D-Galf-(1→5)-D-Galf (51% overall yield, 30 mg, 34 μmol).

20: ¹H NMR (CD₃OD): δ_H 8.11-8.06 (4H, m, H_{pNP}, H_{Bz}), 7.93-7.81 (6H, 3 dd, ³J = 8.3 Hz, ⁴J = 1.2 Hz, H_{Bz}), 7.66 (1H, td, ³J = 7.3 Hz, ⁴J = 1.2 Hz, H_{Bz}), 7.56-7.22 (11H, m, H_{Bz}), 7.03 (2H, d, ³J = 9.3 Hz, H_{pNP}), 5.77 (1H, ddd, $J_{5b,6b} = 7.1$ Hz, $J_{5b,4b} = J_{5b,6'b} = 3.5$ Hz, H-5b), 5.61 (1H, d, $J_{1a,2a} = 2.4$ Hz, H-1a), 5.51 (1H, d, $J_{3b,4b} = 4.7$ Hz, H-3b), 5.41 (1H, s, H-1b), 5.39 (1H,

s, H-2b), 4.60 (1H, dd, $J_{6b,6'b} = 12.1$ Hz, H-6b), 4.42-4.36 (2H, m, H-6'b, H-4b), 4.34 (1H, dd, $J_{4a,3a} = 7.1$ Hz, $J_{4a,5a} = 1.9$ Hz, H-4a), 4.27 (1H, dd, $J_{3a,2a} = 4.9$ Hz, H-3a), 4.15 (1H, dd, H-2a), 4.04 (1H, ddd, $J_{5a,6'a} = 8.6$ Hz, $J_{5a,6a} = 6.2$ Hz, H-5a), 3.92 (1H, app. t., $J_{6a,6'a} = 8.6$ Hz, H-6a), 3.63 (1H, ddd, H-6'a). ^{13}C NMR (CDCl_3) δ_{C} 167.6, 167.2, 167.1, 166.8 (COPh), 163.4 ($\text{C}_{p\text{NP}}$), 143.6 ($\text{C}_{p\text{NP}}$), 134.9, 134.7, 134.6, 134.4, 131.1, 130.8, 130.7, 130.4, 130.3, 129.9, 129.7, 129.5 (C_{Bz}), 126.7, 117.4 ($\text{C}_{p\text{NP}}$), 107.6 (C-1a), 106.3 (C-1b), 84.5 (C-4a), 83.4 (C-2a), 83.3 (C-4b), 83.2 (C-2b), 79.0 (C-3b), 77.1 (C-3a), 71.7 (C-5b), 68.8 (C-5a), 67.4 (C-6a), 64.9 (C-6b).

20': ^1H NMR (CD_3OD) δ_{H} 8.14 (2H, d, $^3J = 9.3$ Hz, $\text{H}_{p\text{NP}}$), 7.96, 7.83, 7.62 (8H, 3 d, $^3J = 7.9$ Hz, H_{Ar}), 7.54-7.27 (12H, m, H_{Ar}), 7.18 (2H, d, $\text{H}_{p\text{NP}}$), 6.06 (1H, d, $J_{1b,2b} = 4.2$ Hz, H-1b), 5.64 (1H, d, $J_{1a,2a} = 1.8$ Hz, H-1a), 5.51 (1H, d, $J_{3b,4b} = 3.3$ Hz, H-3b), 5.43-5.38 (1H, m, H-5b), 5.10 (1H, d, H-2b), 4.66-4.59 (2H, m, H-4b, H-6b), 4.43 (1H, dd, $J_{6'b,6b} = 12.4$ Hz, $J_{6'b,5b} = 5.5$ Hz, H-6'b), 4.27 (1H, dd, $J_{2a,3a} = 4.0$ Hz, H-2a), 4.18 (1H, dd, $J_{3a,4a} = 6.4$ Hz, H-3a), 4.11 (1H, dd, $J_{4a,5a} = 2.5$ Hz, H-4a), 3.86 (1H, app. td., $J_{5a,6a} = 6.8$ Hz, H-5a), 3.51 (1H, dd, $J_{6a,6'a} = 9.4$ Hz, H-6a), 3.40 (1H, dd, H-6'a). ^{13}C NMR (CDCl_3) δ_{C} 167.1, 166.7, 166.7 (COPh), 163.2, 143.5 ($\text{C}_{p\text{NP}}$), 137.2, 134.7, 134.2, 130.7, 130.6, 130.5, 130.5, 130.3, 130.1, 129.6, 129.4, 129.3, 129.1, 127.5 (C_{Ar}), 126.5 ($\text{C}_{p\text{NP}}$), 124.6 (CO_3Ph), 117.5 ($\text{C}_{p\text{NP}}$), 107.5 (C-1a), 106.5 (C-1b), 86.8 (C-2b), 85.2 (C-4a), 84.6 (C-4b), 83.3 (C-2a), 77.9, 77.8 (C-3b, C-3a), 72.7 (C-5b), 69.2 (C-5a), 64.9 (C-6a), 64.0 (C-6b).

Acknowledgment. We are grateful to CNRS and the “Ministère de l’enseignement supérieur et de la recherche” for financial supports, We thanks the “Centre Regional des Mesures Physiques de l’Ouest (Université de Rennes 1)” for the registration of the mass spectra. This work was supported by the French Agence Nationale de la Recherche (ANR-10-BLAN-0718).

1
2
3 **Supporting Information Available:** Details of the computational calculations and ^1H and
4
5 ^{13}C NMR spectra of all new compounds. This material is available free of charge via the
6
7 Internet at <http://pubs.acs.org>.
8
9

10 11 12 **References.**

- 13
14 (1) Acosta-Serrano, A.; Hutchinson, C.; Nakayasu, E. S.; Almeida, I. C.;
15 Carrington, M. In *Trypanosomes- After the Genome*; Barry, D., McCulloch, R., Mottram, J.,
16 Acosta-Serrano, A., Eds.; Horizon Bioscience: **2007**, p 319-337.
17 (2) Cabezas, Y.; Legentil, L.; Robert-Gangneux, F.; Daligault, F.; Belaz, S.;
18 Nugier-Chauvin, C.; Tranchimand, S.; Tellier, C.; Gangneux, J.-P.; Ferrieres, V. *Org. Biomol.*
19 *Chem.* **2015**, *13*, 8393-8404.
20 (3) Cescutti, P. In *Microbial Glycobiology Structure, Relevance and Applications*;
21 Moran, A. P., Ed.; Elsevier: London, **2009**, p 93-108.
22 (4) Tarbell, J. M.; Cancel, L. M. *J. Intern. Med.* **2016**, *280*, 97-113.
23 (5) Richards, M. R.; Lowary, T. L. *ChemBioChem* **2009**, *10*, 1920-1938.
24 (6) Peltier, P.; Euzen, R.; Daniellou, R.; Nugier-Chauvin, C.; Ferrières, V.
25 *Carbohydr. Res.* **2008**, *343*, 1897-1923.
26 (7) Eppe, G.; El Bkassiny, S.; Vincent, S. P. In *Carbohydrates in Drug Design and*
27 *Discovery*; Jiménez-Barbero, J., Cañada, J., Martín-Santamaria, S., Eds.; The Royal society of
28 Chemistry: London, **2015**; Vol. 43, p 209-241.
29 (8) Argunov, D. A.; Krylov, V. B.; Nifantiev, N. E. *Org. Biomol. Chem.* **2015**, *13*,
30 3255-3267.
31 (9) Completo, G. C.; Lowary, T. L. *J. Org. Chem.* **2008**, *73*, 4513-4525.
32 (10) Gandolfi-Donadio, L.; Gallo-Rodriguez, C.; de Lederkremer, R. M. *J. Org.*
33 *Chem.* **2002**, *67*, 4430-4435.
34 (11) Marino, C.; Baldoni, L. *ChemBioChem* **2014**, *15*, 188-204.
35 (12) Ruda, K.; Lindberg, J.; Garegg, P. J.; Oscarson, S.; Konradsson, P. *J. Am.*
36 *Chem. Soc.* **2000**, *122*, 11067-11072.
37 (13) Goto, K.; Sawa, M.; Tamai, H.; Imamura, A.; Ando, H.; Ishida, H.; Kiso, M.
38 *Chem. Eur. J.* **2016**, *22*, 8323-8331.
39 (14) Poulin, M. B.; Lowary, T. L. *J. Org. Chem.* **2016**, *81*, 8123-8130.
40 (15) Yamatsugu, K.; Splain, R. A.; Kiessling, L. L. *J. Am. Chem. Soc.* **2016**, *138*,
41 9205-9211.
42 (16) Chlubnova, I.; Kralova, B.; Dvorakova, H.; Hosek, P.; Spiwok, V.; Filipp, D.;
43 Nugier-Chauvin, C.; Daniellou, R.; Ferrieres, V. *Org. Biomol. Chem.* **2014**, *12*, 3080-3089.
44 (17) Pennec, A.; Daniellou, R.; Loyer, P.; Nugier-Chauvin, C.; Ferrieres, V.
45 *Carbohydr. Res.* **2015**, *402*, 50-55.
46 (18) Kaji, E.; Shibayama, K.; In, K. *Tetrahedron Lett.* **2003**, *44*, 4881-4885.
47 (19) Maggi, A.; Madsen, R. *Eur. J. Org. Chem.* **2013**, 2683-2691.
48 (20) Oshima, K.; Aoyama, Y. *J. Am. Chem. Soc.* **1999**, *121*, 2315-2316.
49 (21) Kaji, E.; Yamamoto, D.; Shirai, Y.; Ishige, K.; Arai, Y.; Shirahata, T.; Makino,
50 K.; Nishino, T. *Eur. J. Org. Chem.* **2014**, 3536-3539.
51 (22) Lee, D.; Taylor, M. S. *J. Am. Chem. Soc.* **2011**, *133*, 3724-3727.
52 (23) Chan, L.; Taylor, M. S. *Org. Lett.* **2011**, *13*, 3090-3093.
53
54
55
56
57
58
59
60

- 1
2
3 (24) Lee, D.; Williamson, C. L.; Chan, L.; Taylor, M. S. *J. Am. Chem. Soc.* **2012**,
4 134, 8260-8267.
5 (25) D'Angelo, K. A.; Taylor, M. S. *J. Am. Chem. Soc.* **2016**, 138, 11058-11066.
6 (26) Euzen, R.; Guégan, J. P.; Ferrières, V.; Plusquellec, D. *J. Org. Chem.* **2007**, 72,
7 5743-5747.
8 (27) Pedersen, L.; Turco, S. *Cell. Mol. Life Sci.* **2003**, 60, 259-266.
9 (28) Lowary, T. L. *Acc. Chem. Res.* **2016**, 49, 1379-1388.
10 (29) Gouliaras, C.; Lee, D.; Chan, L.; Taylor, M. S. *J. Am. Chem. Soc.* **2011**, 133,
11 13926-13929.
12 (30) Marino, C.; Varela, O.; de Lederkremer, R. M. *Tetrahedron* **1997**, 53, 16009-
13 16016.
14 (31) Ferrières, V.; Roussel, M.; Gelin, M.; Plusquellec, D. *J. Carbohydr. Chem.*
15 **2001**, 20, 855-865.
16 (32) Gallo-Rodriguez, C.; Gandolfi, L.; de Lederkremer, R. M. *Org. Lett.* **1999**, 1,
17 245-248.
18 (33) Yang, W.; Mortier, W. J. *J. Am. Chem. Soc.* **1986**, 108, 5708-5711.
19 (34) Fraser-Reid, B. L. In *Handbook of Chemical Glycosylation: Advances in*
20 *Stereoselectivity and Therapeutic Relevance*; Demchenko, A. V., Ed.; Wiley-VCH: Weinheim,
21 **2008**, p 381-415.
22 (35) Gorin, P. A. J. *Can. J. Chem.* **1962**, 40, 275-282.
23 (36) Abronina, P. I.; Sedinkin, S. L.; Podvalnyy, N. M.; Fedina, K. G.; Zinin, A. I.;
24 Torgov, V. I.; Kononov, L. O. *Tetrahedron Lett.* **2011**, 52, 1794-1796.
25 (37) Simerská, P.; Kuzma, M.; Pišvejcová, A.; Weignerová, L.; Macková, M.; Riva,
26 S.; Křen, V. *Folia Microbiol. (Praha)* **2003**, 48, 329-337.
27 (38) Simerská, P.; Pišvejcová, A.; Kuzma, M.; Sedmera, P.; Křen, V. r.; Nicotra, S.;
28 Riva, S. *J. Mol. Catal. B: Enzym.* **2004**, 29, 219-225.
29 (39) Chen, H.-M.; Withers, S. G. *Carbohydr. Res.* **2007**, 342, 2212-2222.
30 (40) Poláková, M.; Beláňová, M.; Petruš, L.; Mikušová, K. *Carbohydr. Res.* **2010**,
31 345, 1339-1347.
32 (41) Watt, J. A.; Williams, S. J. *Org. Biomol. Chem.* **2005**, 3, 1982-1992.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60